Results 71 to 80 of about 2,071 (176)

Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-Inhibitors for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons

Rheumatology and Therapy
Introduction Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A and was approved to treat patients with active psoriatic arthritis (PsA) in the European Union in 2023.
Jorge Mestre-Ferrandiz, Victoria Navarro-Compán, Yoana Ivanova-Markova, Almudena González-Domínguez, Stefano Maratia   +4 more
doaj   +1 more source

Bimekizumab 2‐year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Raj Chovatiya, Afsaneh Alavi, Takuya Miyagawa, Irina Turchin, Thrasyvoulos Tzellos, Hessel H. van der Zee, Christina Crater, Bartosz Lukowski, Nicola Tilt, Christos C. Zouboulis   +9 more
wiley   +1 more source

Treatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab

International audienceImportance Palmoplantar pustulosis (PPP) and palmoplantar plaque psoriasis with pustules remain challenging to treat. Studies suggest that an interleukin 17 or interleukin 36 loop acts synergistically in these diseases to induce ...
Goujon, Catherine, Ruer, Mireille, Villani, Axel, Jullien, Denis, Boyé, Thierry, Passeron, Thierry, Perrot, Jean-Luc, Quiles Tsimaratos, Nathalie   +7 more
core   +1 more source

Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysis

Bimekizumab, a humanized monoclonal IgG1 antibody targeting both interleukin (IL)-17A and IL-17F, could be effective for treating Psoriatic arthritis (PsA).
Jia-Jing Cao (18421142), Liu Yang (23752), Ting-Yu Cao (18421133), He-Yi Zhang (18420228), Yue-Hong Huo (18421145), Qin-Yi Su (14188151), Zhuo-Chen Han (18421139), Hai-Ying Dang (18421136), Ting Cheng (1692172), Sheng-Xiao Zhang (8832449)   +9 more
core   +1 more source

Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study

Journal of Dermatological Treatment
Objectives Bimekizumab, a dual interleukin (IL)-17A/IL-17F inhibitor, has demonstrated clinical efficacy in clinical trials. However, real-world evidence comparing outcomes according to previous biologic exposure remains limited.
Emanuele Trovato, Antonella Di Cesare, Salvatore Panduri, Leonardo Pescitelli, Federica Ricceri, Sofia Lo Conte, Luca Brandini, Aldo Cuccia, Marco Romanelli, Pietro Rubegni, Francesca Prignano   +10 more
doaj   +1 more source

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Rheumatology and Therapy
Introduction Matching-adjusted indirect comparisons (MAIC) were used to assess the relative efficacy of bimekizumab 160 mg every 4 weeks (Q4W) compared to guselkumab 100 mg Q4W or every 8 weeks (Q8W) at 48/52 weeks in patients with psoriatic arthritis ...
Richard B. Warren, Iain B. McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Philip J. Mease   +8 more
doaj   +1 more source

Bimekizumab for Hidradenitis Suppurativa: Pathophysiology and Promising Interventions

Hidradenitis suppurativa (HS) is a debilitating dermatologic disorder characterized by recurrent inflammation that affects the apocrine glands and hair follicles and profoundly impacts patients\u27 quality of life.
Fardos, Mohammad, Ismaili, Ameije, Moon, Summer   +2 more
core   +1 more source

Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.

OBJECTIVES: To understand the relative efficacy and safety of bimekizumab, a selective inhibitor of interleukin-17F in addition to IL-17A, vs other biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for psoriatic arthritis
Laliman-Khara, Victor, Coates, Laura C, Gladman, Dafna D, Merola, Joseph F, Willems, Damon, Taieb, Vanessa, Grieve, Stacy, Prickett, Adam R, Nash, Peter, Mease, Philip   +9 more
core   +1 more source

Predictive factors for early super response to bimekizumab in 341 patients with psoriasis—a 24-week short-term multicenter real-life experience

Journal of Dermatological Treatment
Purpose/Aim of the study: The efficacy of bimekizumab was shown in moderate to severe plaque psoriasis. The aim of this study was to investigate the early super responder (ESR) profile (at week 4) to bimekizumab.Materials and Methods: We performed a ...
Tubanur Çetinarslan, Muhammed Ali Mergen, Aylin Türel Ermertcan, Emel Bülbül Başkan, Serkan Yazıcı, İsa An, Gülhan Gürel, Esra Adışen, Abdullah Demirbaş, Recep Dursun, Bahadır Aslancan, Zeynep Topkarcı, Mustafa Esen, Zafer Türkoğlu, Dilek Canat, Selim Kandiş, Arzu Kılıç, İlgen Ertam Sağduyu, Elif Irmak Yazıcı, Ece Gökyayla, Neslihan Demirel Öğüt, Özge Sevil Karstarlı Bakay, Selami Aykut Temiz, Vefa Aslı Erdemir, Fatma Aslı Hapa, Ömer Aydin, Pelin Hızlı, Berna Solak, Melike Bütüner, Sema Aytekin, Hülya Albayrak, Munise Daye, Ümit Türsen, Ayşe Nur Sarıbaş Yıldırım, Beyhan Cengiz Özyurt   +34 more
doaj   +1 more source

Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison

Rheumatology and Therapy
Introduction Matching-adjusted indirect comparisons (MAICs) were used to compare the efficacy of bimekizumab and secukinumab 150 mg and 300 mg at 52 weeks for the treatment of psoriatic arthritis (PsA) in patients who were biologic disease-modifying anti-
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes   +8 more
doaj   +1 more source